CD47KO/CRT dual-bioengineered cell membrane-coated nanovaccine combined with anti-PD-L1 antibody for boosting tumor immunotherapy
Tumor vaccines trigger tumor-specific immune responses to prevent or treat tumors by activating the hosts’ immune systems, and therefore, these vaccines have potential clinical applications. However, the low immunogenicity of the tumor antigen itself and the low efficiency of the vaccine delivery sy...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
KeAi Communications Co., Ltd.
2023-04-01
|
| Series: | Bioactive Materials |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2452199X22004133 |
| _version_ | 1797204427614978048 |
|---|---|
| author | Shengyang Liu Jiayan Wu Yuanji Feng Xiaoya Guo Tong Li Meng Meng Jie Chen Daquan Chen Huayu Tian |
| author_facet | Shengyang Liu Jiayan Wu Yuanji Feng Xiaoya Guo Tong Li Meng Meng Jie Chen Daquan Chen Huayu Tian |
| author_sort | Shengyang Liu |
| collection | DOAJ |
| description | Tumor vaccines trigger tumor-specific immune responses to prevent or treat tumors by activating the hosts’ immune systems, and therefore, these vaccines have potential clinical applications. However, the low immunogenicity of the tumor antigen itself and the low efficiency of the vaccine delivery system hinder the efficacy of tumor vaccines that cannot produce high-efficiency and long-lasting antitumor immune effects. Here, we constructed a nanovaccine by integrating CD47KO/CRT dual-bioengineered B16F10 cancer cell membranes and the unmethylated cytosine-phosphate-guanine (CpG) adjuvant. Hyperbranched PEI25k was used to load unmethylated cytosine-phosphate-guanine (CpG) through electrostatic adsorption to prepare PEI25k/CpG nanoparticles (PEI25k/CpG-NPs). CD47KO/CRT dual-bioengineered cells were obtained by CRISPR-Cas9 gene editing technology, followed by the cell surface translocation of calreticulin (CRT) to induce immunogenic cell death (ICD) in vitro. Finally, the extracted cell membranes were coextruded with PEI25k/CpG-NPs to construct the CD47KO/CRT dual-bioengineered cancer cell membrane-coated nanoparticles (DBE@CCNPs). DBE@CCNPs could promote endocytosis of antigens and adjuvants in murine bone marrow derived dendritic cells (BMDCs) and induce their maturation and antigen cross-presentation. To avoid immune checkpoint molecule-induced T cell dysfunction, the immune checkpoint inhibitor, the anti-PD-L1 antibody, was introduced to boost tumor immunotherapy through a combination with the DBE@CCNPs nanovaccine. This combination therapy strategy can significantly alleviate tumor growth and may open up a potential strategy for clinical tumor immunotherapy. |
| first_indexed | 2024-04-10T20:57:11Z |
| format | Article |
| id | doaj.art-e6331b4abd6c427683146e54c089922c |
| institution | Directory Open Access Journal |
| issn | 2452-199X |
| language | English |
| last_indexed | 2024-04-24T08:35:03Z |
| publishDate | 2023-04-01 |
| publisher | KeAi Communications Co., Ltd. |
| record_format | Article |
| series | Bioactive Materials |
| spelling | doaj.art-e6331b4abd6c427683146e54c089922c2024-04-16T17:41:31ZengKeAi Communications Co., Ltd.Bioactive Materials2452-199X2023-04-0122211224CD47KO/CRT dual-bioengineered cell membrane-coated nanovaccine combined with anti-PD-L1 antibody for boosting tumor immunotherapyShengyang Liu0Jiayan Wu1Yuanji Feng2Xiaoya Guo3Tong Li4Meng Meng5Jie Chen6Daquan Chen7Huayu Tian8School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai, 264005, PR China; Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, 130022, PR ChinaKey Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, 130022, PR ChinaKey Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, 130022, PR ChinaKey Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, 130022, PR China; College of Chemistry and Chemical Engineering, Xiamen University, Xiamen, 361005, PR ChinaKey Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, 130022, PR China; College of Chemistry and Chemical Engineering, Xiamen University, Xiamen, 361005, PR ChinaKey Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, 130022, PR China; College of Chemistry and Chemical Engineering, Xiamen University, Xiamen, 361005, PR ChinaKey Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, 130022, PR China; Corresponding author.School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai, 264005, PR China; Corresponding author.Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, 130022, PR China; College of Chemistry and Chemical Engineering, Xiamen University, Xiamen, 361005, PR China; Corresponding author. Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, 130022, PR China.Tumor vaccines trigger tumor-specific immune responses to prevent or treat tumors by activating the hosts’ immune systems, and therefore, these vaccines have potential clinical applications. However, the low immunogenicity of the tumor antigen itself and the low efficiency of the vaccine delivery system hinder the efficacy of tumor vaccines that cannot produce high-efficiency and long-lasting antitumor immune effects. Here, we constructed a nanovaccine by integrating CD47KO/CRT dual-bioengineered B16F10 cancer cell membranes and the unmethylated cytosine-phosphate-guanine (CpG) adjuvant. Hyperbranched PEI25k was used to load unmethylated cytosine-phosphate-guanine (CpG) through electrostatic adsorption to prepare PEI25k/CpG nanoparticles (PEI25k/CpG-NPs). CD47KO/CRT dual-bioengineered cells were obtained by CRISPR-Cas9 gene editing technology, followed by the cell surface translocation of calreticulin (CRT) to induce immunogenic cell death (ICD) in vitro. Finally, the extracted cell membranes were coextruded with PEI25k/CpG-NPs to construct the CD47KO/CRT dual-bioengineered cancer cell membrane-coated nanoparticles (DBE@CCNPs). DBE@CCNPs could promote endocytosis of antigens and adjuvants in murine bone marrow derived dendritic cells (BMDCs) and induce their maturation and antigen cross-presentation. To avoid immune checkpoint molecule-induced T cell dysfunction, the immune checkpoint inhibitor, the anti-PD-L1 antibody, was introduced to boost tumor immunotherapy through a combination with the DBE@CCNPs nanovaccine. This combination therapy strategy can significantly alleviate tumor growth and may open up a potential strategy for clinical tumor immunotherapy.http://www.sciencedirect.com/science/article/pii/S2452199X22004133CRISPR–Cas9Dual-bioengineered cell membraneImmune checkpoint blockadeNanovaccineTumor immunotherapy |
| spellingShingle | Shengyang Liu Jiayan Wu Yuanji Feng Xiaoya Guo Tong Li Meng Meng Jie Chen Daquan Chen Huayu Tian CD47KO/CRT dual-bioengineered cell membrane-coated nanovaccine combined with anti-PD-L1 antibody for boosting tumor immunotherapy Bioactive Materials CRISPR–Cas9 Dual-bioengineered cell membrane Immune checkpoint blockade Nanovaccine Tumor immunotherapy |
| title | CD47KO/CRT dual-bioengineered cell membrane-coated nanovaccine combined with anti-PD-L1 antibody for boosting tumor immunotherapy |
| title_full | CD47KO/CRT dual-bioengineered cell membrane-coated nanovaccine combined with anti-PD-L1 antibody for boosting tumor immunotherapy |
| title_fullStr | CD47KO/CRT dual-bioengineered cell membrane-coated nanovaccine combined with anti-PD-L1 antibody for boosting tumor immunotherapy |
| title_full_unstemmed | CD47KO/CRT dual-bioengineered cell membrane-coated nanovaccine combined with anti-PD-L1 antibody for boosting tumor immunotherapy |
| title_short | CD47KO/CRT dual-bioengineered cell membrane-coated nanovaccine combined with anti-PD-L1 antibody for boosting tumor immunotherapy |
| title_sort | cd47ko crt dual bioengineered cell membrane coated nanovaccine combined with anti pd l1 antibody for boosting tumor immunotherapy |
| topic | CRISPR–Cas9 Dual-bioengineered cell membrane Immune checkpoint blockade Nanovaccine Tumor immunotherapy |
| url | http://www.sciencedirect.com/science/article/pii/S2452199X22004133 |
| work_keys_str_mv | AT shengyangliu cd47kocrtdualbioengineeredcellmembranecoatednanovaccinecombinedwithantipdl1antibodyforboostingtumorimmunotherapy AT jiayanwu cd47kocrtdualbioengineeredcellmembranecoatednanovaccinecombinedwithantipdl1antibodyforboostingtumorimmunotherapy AT yuanjifeng cd47kocrtdualbioengineeredcellmembranecoatednanovaccinecombinedwithantipdl1antibodyforboostingtumorimmunotherapy AT xiaoyaguo cd47kocrtdualbioengineeredcellmembranecoatednanovaccinecombinedwithantipdl1antibodyforboostingtumorimmunotherapy AT tongli cd47kocrtdualbioengineeredcellmembranecoatednanovaccinecombinedwithantipdl1antibodyforboostingtumorimmunotherapy AT mengmeng cd47kocrtdualbioengineeredcellmembranecoatednanovaccinecombinedwithantipdl1antibodyforboostingtumorimmunotherapy AT jiechen cd47kocrtdualbioengineeredcellmembranecoatednanovaccinecombinedwithantipdl1antibodyforboostingtumorimmunotherapy AT daquanchen cd47kocrtdualbioengineeredcellmembranecoatednanovaccinecombinedwithantipdl1antibodyforboostingtumorimmunotherapy AT huayutian cd47kocrtdualbioengineeredcellmembranecoatednanovaccinecombinedwithantipdl1antibodyforboostingtumorimmunotherapy |